Pemetrexed

Generic Name: Pemetrexed

Brand Names: Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁N_₅O_₆

CAS Number: 137281-23-3

Unique Ingredient Identifier: 04Q9AIZ7NO

Background: Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.

Indication: Pemetrexed is indicated for the treatment of the following conditions:

Non-squamous non-small cell lung cancer (NSCLC)

Malignant pleural mesothelioma

Associated Conditions: Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma

Associated Therapies: Monotherapy

Clinical Trials

A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy

Phase 3

Completed

Conditions: Non-Small-Cell Lung Carcinoma

Interventions: Biological: Nivolumab
Biological: Ipilimumab
Drug: Pemetrexed
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2016-08-11

Last Posted Date: 2023-09-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 367

Registration Number: NCT02864251

Locations: 🇺🇸
Local Institution - 0033, Los Angeles, California, United States
🇺🇸
Torrance Memorial Physican Network, Redondo Beach, California, United States
🇺🇸
Baylor Scott and White Research Institute, Temple, Texas, United States

and more 48 locations

Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for MPM

Phase 1

Terminated

Conditions: Mesothelioma

Interventions: Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2016-07-20

Last Posted Date: 2022-03-31

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 7

Registration Number: NCT02838745

Locations: 🇺🇸
Baylor St Lukes, Houston, Texas, United States

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Phase 1

Recruiting

Conditions: Neoplasms

Interventions: Drug: TSR-022
Drug: TSR-042
Drug: Nivolumab
Drug: TSR-033
Drug: Docetaxel
Drug: Pemetrexed
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2016-06-29

Last Posted Date: 2024-06-20

Lead Sponsor: Tesaro, Inc.

Target Recruit Count: 447

Registration Number: NCT02817633

Locations: 🇨🇳
GSK Investigational Site, Tainan, Taiwan

Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors

Phase 1

Completed

Conditions: Advanced/Metastatic Tumors

Interventions: Drug: Tiragolumab
Drug: Atezolizumab
Drug: Pembrolizumab
Drug: Carboplatin
Drug: Capecitabine
Drug: Bevacizumab
Drug: Cisplatin
Drug: Paclitaxel
Drug: Pemetrexed
Drug: Etoposide

First Posted Date: 2016-06-09

Last Posted Date: 2024-12-05

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 518

Registration Number: NCT02794571

Locations: 🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

and more 25 locations

A Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Docetaxel Consolidation in Patients With Inoperable Squamous Cell Lung Cancer

Phase 2

Conditions: Squamous Cell Lung Cancer

Interventions: Drug: pemetrexed
Drug: cisplatin
Radiation: thoracic radiation therapy
Drug: docetaxel

First Posted Date: 2016-06-01

Last Posted Date: 2016-11-25

Lead Sponsor: First People's Hospital of Hangzhou

Target Recruit Count: 54

Registration Number: NCT02787473

Locations: 🇨🇳
Hangzhou First People's Hospital, Hangzhou, Zhejiang, China

Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

Phase 2

Completed

Conditions: Mesothelioma

Interventions: Drug: Cisplatin
Drug: Pemetrexed
Drug: Pembrolizumab

First Posted Date: 2016-05-26

Last Posted Date: 2024-12-10

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 520

Registration Number: NCT02784171

Locations: 🇨🇦
BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada
🇫🇷
Institut Gustave-Roussy, Villejuif, FR, France
🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada

and more 53 locations